Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 8/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049480 | 0.87 | L3MBTL1 (0.76) | MEN1KMT2AL3MBTL1CCR5LMNA | |
| SCHEMBL5049557 | 0.85 | L3MBTL1 (0.74) | MEN1KMT2AL3MBTL1CCR5LMNA | |
| SCHEMBL14297341 | 0.82 | NPC1 (0.55) | MEN1KMT2ACCR5NPC1RAB9A | |
| SCHEMBL7603229 | 0.79 | MEN1 (0.63) | MEN1KMT2AL3MBTL1CCR5KCNH2 | |
| SCHEMBL7601798 | 0.78 | L3MBTL1 (0.64) | MEN1KMT2AL3MBTL1CCR5LMNA | |
| SCHEMBL8356511 | 0.77 | KMT2A (0.60) | MEN1KMT2AL3MBTL1CCR5LMNA | |
| SCHEMBL14032000 | 0.77 | CCR5 (0.84) | CCR5 | |
| SCHEMBL30090134 | 0.75 | L3MBTL1 (0.58) | MEN1KMT2AL3MBTL1LMNANPC1 | |
| SCHEMBL2352527 | 0.74 | L3MBTL1 (0.75) | MEN1KMT2AL3MBTL1CCR5LMNA | |
| SCHEMBL8356513 | 0.74 | KMT2A (0.54) | MEN1KMT2AL3MBTL1CCR5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | MEN1 3791/4885KMT2A 1652/4885L3MBTL1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.